




RFP-PD-2014-001

Intent to Apply (ITA)




A total of 16 eligible ITA forms were received. A breakdown of eligible ITA forms by disease, intervention and development stage is shown below: *



* One or more ITA included multiple diseases, interventions and/or development stages in the scope.

Full Proposal

A total of 15 eligible proposals were received. A breakdown of eligible proposals by disease, intervention and development stage is shown below:*



* One or more proposal included multiple diseases, interventions and/or development stages in the scope.

Award Notification

The following seven projects were awarded funding.

Project Title	Collaboration Partners	Disease	Intervention	Development Stage	Total Amount
Development of a Live Attenuated Tetravalent Dengue Vaccine	1. The Chemo-Sero-Therapeutic Research Institute (KAKETSUKEN) 2. Center for Vaccine Development, Institute of Molecular Biosciences, Mahidol University	Dengue fever	Vaccine	Pre-Clinical (Lead Optimization-IND)	¥345,027,667
Preclinical and clinical development of (+)-SJ000557733, a novel inhibitor of Plasmodium ATP4	1. St Jude Children's Research Hospital 2. Eisai Co Ltd 3. Medicines for Malaria Venture (MMV)	Malaria	Drug	Pre-Clinical (Lead Optimization-IND), Clinical (Ph1)	¥376,892,206
Lead optimization of a novel mechanism-of-action antimalarial	1. Broad Institute 2. Eisai Co. Ltd	Malaria	Drug	Pre-Clinical (Lead Optimization-IND)	¥299,752,512
Testing DSM265, a novel antimalarial acting through DHODH, in combination with OZ439	1. Medicines for Malaria Venture (MMV) 2. Takeda Pharmaceutical Company Limited	Malaria	Drug	Clinical (Ph1)	¥129,088,303
Clinical development of the BK-SE36 malaria vaccine candidate	1. European Vaccine Initiative (EVI) 2. Research Institute for Microbial Diseases (RIMD) 3. Centre National de Recherche et de Formation sur le Paludisme (CNRFP)	Malaria	Vaccine	IND - Clinical (Ph1)	¥99,999,999
Accelerating Development of Transmission-Blocking Vaccines for Malaria Elimination Using a Novel Vaccine Candidate	1. PATH Malaria Vaccine Initiative 2. Ehime University	Malaria	Vaccine	Pre-Clinical (Lead Optimization-IND)	¥76,609,856
Adjuvant Technologies to Advance Chagas Disease Vaccine Development	1. Sabin Vaccine Institute 2. Baylor College of Medicine (BCM) 3. Eisai Co. Ltd. 4. Aeris	Chagas disease	Vaccine	Pre-Clinical (Lead Optimization-IND)	¥200,000,000